You are here

IGF OT IGF ESTABLISHMENT OF CANCER CELL LINES FOR ADVANCING OVARIAN CANCER HEALTH DISPARITY RESEARCH

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201600039C-0-0-0
Agency Tracking Number: N43CA160039
Amount: $224,869.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3853 DWIGHT CT
MOBILE, AL 36619-1734
United States
DUNS: 079992109
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KATHLEEN SEARS
 (251) 545-3137
 apsingh01@yahoo.com
Business Contact
 KATHLEEN SEARS
Phone: (251) 545-3137
Email: apsingh01@yahoo.com
Research Institution
N/A
Abstract

Ovarian cancer OC disproportionately affects the women of African American AA background at all stages of the disease from presentation through treatment Most upsetting fact is that AA patients have greater mortality and their survival rates are continuously decreasing as compared to Caucasian American CA Success in understanding and characterizing the involved mechanisms in existing racial disparity is greatly hampered by the lack of suitable cell line models Therefore our specific objective of this SBIR Phase I proposal is to standardize the procedure and collaborative set up for developing novel ovarian cancer cell lines to advance OC health disparity research This will be achieved in two parts A development of in vitro cell line experimental model of ovarian cancer and fibroblast cells from freshly resected tumors ascites fluid of AA patients B Genetic characterization of newly developed cells by isoenzyme profiling Karyotyping short tandem repeat profiling and mutational analysis Moreover we will characterize the developed cell line for typical morphology growth rates population doubling time tumorigenic and metastatic potential and drug sensitivities Successful completion of the proposed research would establish a standardized protocol for generation of novel cell line models of OC and thus provide a strong foundation for our next step i e Phase II for developing up to cell line models from patients of AA backgrounds as well as genetic admixtures

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government